Presented first-in-class clinical proof-of-concept data in KRAS G12D mutant CRC with combination of QTX3034 and anti-EGFR ± ...

FLAURA2 shows early EGFR ctDNA clearance is prognostic but does not predict benefit from adding chemotherapy to first-line ...

While there are many aspects of CKD dietary therapy that are difficult in practice, I believe there are many points to ...

COCOON shows lazertinib lead-in plus simplified prophylaxis reduced grade ≥2 skin toxicity to 18% with SC amivantamab in EGFR ...

Sequencing of tumor tissue from 107 glioma patients reveals microbial signatures linked to tumor grade and survival, with ...

Genmab and Incyte will co-develop a Phase 1/2 trial combining petosemtamab, INCB161734, and chemotherapy for KRAS G12D-mutant ...

Esophageal basaloid squamous cell carcinoma, one of the rarest and most aggressive forms of esophageal cancer, has long ...

BG-C477 is the first ADC to emerge from BeOne’s internal drug discovery organization. With a proprietary CEA (or CEACAM5) targeting antibody, a highly stable conjugator, and a cleavable linker, ...

Pope Leo XIV's lung cancer diagnosis has renewed attention on non-smokers, who can face delayed diagnoses despite risks including radon, genetics, second-hand smoke and pollution.

ArriVent BioPharma disclosed that its global Phase 3 FURVENT trial did not meet its primary endpoint, prompting a law firm to ...

Landmark results from the DeLLphi-305 Phase III trial showed IMFINZI® (durvalumab) plus Amgen’s tarlatamab-dlle demonstrated a statistically significant and highly clinically meaningful improvement in ...

New research indicates that commonly used measures of kidney function underestimate the prevalence of chronic kidney disease ...